TY - JOUR AU - Kotaka, Masahito AU - Xu, Ruihua AU - Muro, Kei AU - Park, Young Suk AU - Morita, Satoshi AU - Iwasa, Satoru AU - Uetake, Hiroyuki AU - Nishina, Tomohiro AU - Nozawa, Hiroaki AU - Matsumoto, Hiroshi AU - Yamazaki, Kentaro AU - Han, Sae-Won AU - Wang, Wei AU - Ahn, Joong Bae AU - Deng, Yanhong AU - Cho, Sang-Hee AU - Ba, Yi AU - Lee, Keun-Wook AU - Zhang, Tao AU - Satoh, Taroh AU - Buyse, Marc E. AU - Ryoo, Baek-Yeol AU - Shen, Lin AU - Sakamoto, Junichi AU - Kim, Tae Won PY - 2016 DA - 2016/12/22 TI - Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab JO - Chinese Journal of Cancer SP - 102 VL - 35 IS - 1 AB - Capecitabine and irinotecan combination therapy (XELIRI) has been examined at various dose levels to treat metastatic colorectal cancer (mCRC). Recently, in the Association of Medical Oncology of the German Cancer Society (AIO) 0604 trial, tri-weekly XELIRI plus bevacizumab, with reduced doses of irinotecan (200 mg/m2 on day 1) and capecitabine (1600 mg/m2 on days 1–14), repeated every 3 weeks, has shown favorable tolerability and efficacy which were comparable to those of capecitabine and oxaliplatin (XELOX) plus bevacizumab. The doses of capecitabine and irinotecan in the AIO trial are considered optimal. In a phase I/II study, XELIRI plus bevacizumab (BIX) as second-line chemotherapy was well tolerated and had promising efficacy in Japanese patients. SN - 1944-446X UR - https://doi.org/10.1186/s40880-016-0166-3 DO - 10.1186/s40880-016-0166-3 ID - Kotaka2016 ER -